Tipifarnib
Cat.No:IT1440 Solarbio
CAS:192185-72-1
Molecular Formula:C27H22Cl2N4O
Molecular Weight:489.4
Storage:Powder:-20℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥99%
Appearance:White to yellow Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Metabolic Enzyme & Protease >
TipifarnibCAS:192185-72-1
Molecular Formula:C27H22Cl2N4O
Molecular Weight:489.4
Storage:Powder:-20℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥99%
Appearance:White to yellow Solid
Qty:
Size:
CAS | 192185-72-1 |
Name | Tipifarnib |
Molecular Formula | C27H22Cl2N4O |
Molecular Weight | 489.4 |
Solubility | Soluble in DMSO |
Purity | ≥99% |
Appearance | White to yellow Solid |
Storage | Powder:-20℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL | MFCD07772347 |
SMILES | O=C1N(C2=C(C(C3=CC=CC(Cl)=C3)=C1)C=C(C=C2)[C@@](N)(C4=CN=CN4C)C5=CC=C(C=C5)Cl)C |
Target Point | Farnesyl Transferase |
Passage | Metabolic Enzyme&Protease |
Background | Tipifarnib is a potent and specific farnesyltransferase (FTase) inhibitor. |
Biological Activity | Tipifarnib 是一种有效的, 特异性的 farnesyltransferase (FTase) 抑制剂, IC50 值为 0.6 nM[1-6]。 |
IC50 | IC50: 0.6nM (FTase) [1-6] |
In Vitro | 与DMSO处理的LGL T细胞相比,替比法尼(5μM)导致药物处理的凋亡细胞百分比显着更高。使用来自健康供体的T细胞,替比法尼以时间依赖性方式降低IFNγ阳性细胞的百分比。与DMSO相比,替比法尼降低了沉淀物中活化的Ras的量[2]。替比法尼在浓度小于10nM时对克隆MDS造血作用具有选择性体外毒性,其效果在白细胞祖细胞中更为突出。这种作用不是由于细胞凋亡诱导,因为正常和MDS祖细胞在暴露于替比法尼后72小时内显示出相当的DiOC3和膜联蛋白V表达[3]。在E2存在下将Tipifarnib与10 nM 4-OH-他莫昔芬组合可将IC50从400降低至50 nM [4]。替比法尼诱导U937细胞凋亡[5]。此外,Tipifarnib抑制分离的人类法呢基转移酶用于核纤层蛋白B肽和K-RasB肽,IC50分别为0.86 nM和7.9 nM [6]。 |
In Vivo | Tipifarnib具有适用于患者的适度毒性和小鼠中移植物抗宿主病的有效减少,并且它可以显着减少移植物抗宿主病,而不会对免疫重建产生负面影响[1]。与单独使用任一种药物相比,联合用他莫昔芬和替比法尼(50 mg / kg,po)治疗可产生更大的肿瘤生长抑制作用。 E2剥夺和替比法尼组合导致比E2剥夺或单独的替比法尼更大的生长抑制。与单用他莫昔芬或替比法尼相比,他莫昔芬和替比法尼的组合导致Ki-67显着降低。与对照相比,单独的替比法尼也降低了CTI。他莫昔芬联合替比法尼或替比法尼联合E2戒断治疗最有效降低CTI(分别为0.8和0.7),这可能是肿瘤体积减少的原因[4]。 |
Cell Experiment | 将类固醇耗尽的细胞以每孔1×10 4个细胞的密度接种到12孔板中,或以葡聚糖包被的木炭培养基以每孔4,000个细胞的密度接种到96孔板中。 24小时后,单独或组合用E2加抑制剂处理单层。将12孔板处理6天,每天更换。然后使用Z1 Coulter计数器确定细胞数。用单剂量处理96孔板并放置96小时,此时使用如前所述的溴化3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑 测定法测量细胞活力。 Tipifarnib和4-OH-三苯氧胺之间的相互作用通过Chou和Talalay描述的中值效应图法分析。组合指数的计算考虑了非固定药物比例,并且基于两种药物的作用对于严格检测协同作用而言是相互非排他性的假设。组合指数 1表示拮抗作用。实验重复三次。 |
Animal Experiment | 将雌性切除卵巢的Ncr foxhead裸鼠保持在无菌条件下,自由获取食物和水。通过植入来自已建立的肿瘤的2mm直径肿瘤片段来启动MCF-7异种移植物。通过id注射17β-雌二醇颗粒(剂量1.7mg,持续60天)通过E2补充维持肿瘤生长。一旦肿瘤直径达到7毫米,小鼠随机接受载体[20%w /vβ-环糊精(pH 2.5)用于替比法尼,50%PEG 300,50%H2O + 1滴1N HCl每3 mL用于他莫昔芬],替比法尼(50 mg / kg每日两次),他莫昔芬(20 mg / kg),或替比法尼和他莫昔芬的组合。两个进一步的治疗臂用于评估E2戒断(去除E2沉淀)或E2戒断与替比法尼(50mg / kg每天两次)联合的效果。所有药物通过口服强饲法每天连续5天给药,然后是2天的休息期,共19天。实验进行两次,得到相似的结果; 因此,将增长数据结合起来进行统计分析。每组中有6只荷瘤动物,并且在第19天收获所有肿瘤。使用公式a×b2×π/ 6计算肿瘤体积,其中a和b是正交肿瘤直径并表示为体积的百分比在治疗开始时(相对肿瘤体积)。使用Kruskal-Wallace检验计算总体统计学差异,并使用Mann-Whitney检验计算各个治疗组之间的统计学差异。 |
Data Literature Source | [1]. Hechinger AK, et al. Inhibition of protein geranylgeranylation and farnesylation protects against GvHD via effects on CD4 effector T cells. Haematologica. 2012 Jul 16. [2]. Bai F, et al. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immunother. 2012 Apr; 61 (4) :523-33. [3]. Kotsianidis I, et al. In vitro effects of the farnesyltransferase inhibitor tipifarnib on myelodysplastic syndrome progenitors. Acta Haematol. 2008; 120 (1) :51-6. [4]. Martin LA, et al. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther. 2007 Sep; 6 (9) :2 [5]. Krzykowska-Petitjean K, et al. Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells. J Cancer Res Clin Oncol. 2012 Mar; 138 (3) :537-44. [6]. End DW, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001 Jan 1; 61 (1) :131-7. |
Unit | Bottle |
Specification | 5mg 10mg 50mg |
Tipifarnib 是一种有效的,特异性的 farnesyltransferase (FTase) 抑制剂。
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.